Ultrahuman hires chief business officer as it scales expansion for glucose monitoring tech

[Image from Ultrahuman]Metabolic tracking technology developer Ultrahuman announced today that it appointed Bhuvan Srinivasan as its first chief chief business officer.

The appointment of Srinivasan to the new role follows Bangalore, India-based Ultrahuman’s $17.5 million Series B financing round completed in August.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet announces board of director changes

Insulin delivery technology developer Insulet (NSDQ:PODD) announced today that it appointed Dr. Luciana Borio to its board of directors.

Borio joins the board of Acton, Massachusetts-based Insulet, having served in key roles with the FDA, the National Security Council and the Council on Foreign Relations. She specializes in biodefense and medical countermeasures, emerging infectious diseases, medical product development and public health emergencies.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Navidea names two appointments to its board of directors

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors.

Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders’ meeting.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

A Medtronic SVP leaves to become CFO of Caris Life Sciences

Caris Life Sciences announced today that it appointed former Medtronic (NYSE:MDT) executive Mike Weinstein as EVP & CFO.

Weinstein, a veteran of more than 25 years in finance and life sciences, previously joined as SVP of strategy at Medtronic and was a member of the medtech giant’s executive committee, where he oversaw global strategy for the organization, which included providing counsel and input on business development, capital deployment and overall strategic direction for each of Medtronic’s businesses, according to a news release.

Before Medtronic, Weinstein held the role of managing director at JPMorgan Chase, leading the firm’s healthcare group within equity research.

“We are thrilled to welcome Mike to the Caris team,” Caris chairman & CEO David D. Halbert said in the release. “His passion for our mission, industry experience and strategic thinking will provide strong leadership as we position Caris for the next phase;…

Read more
  • 0

Asensus Surgical’s board chair is leaving

Asensus Surgical (NYSE:ASXC) announced that Paul LaViolette, the company’s board chair, will step down from his position.

LaViolette, who has served as the chair of the board since 2013, will step down as chair later this month and intends to leave the board before the end of the year due to other professional commitments. According to a news release, the board intends to appoint David Milne, an existing board member, as the company’s chair after LaViolette steps down.

“It has been a remarkable journey being a part of this organization over the last 8 years and I have valued my time spent on the board,” LaViolette said in the release. “The company has evolved multiple times and is now in a position to revolutionize the way surgery is being performed. I’m confident the team will deliver on the promise of Performance-Guided Surgery through the continued development of Senhance. I wish David, Anthony, and the rest of the organization the best.”

Read more
  • 0

NIH director Francis Collins to step down

The National Institutes of Health (NIH) announced today that Dr. Francis S. Collins will step down as director of the agency.

Collins, the longest-serving presidentially-appointed NIH director, decided to end his tenure by the end of the year. He had served three U.S. presidents over more than 12 years.

NIH did not announce a successor to Collins or a timeline for appointing one.

“It has been an incredible privilege to lead this great agency for more than a decade,” Collins said in a news release. “I love this agency and its people so deeply that the decision to step down was a difficult one, done in close counsel with my wife, Diane Baker, and my family. I am proud of all we’ve accomplished. I fundamentally believe, however, that no single person should serve in the position too long, and that it’s time to bring in a new scientist to lead the NIH into the future.

“I’m most grateful and proud of the NIH staff and the scientific community, wh…

Read more
  • 0

Former Medtronic and Zimmer-Biomet VP joins back pain startup as CEO

Jeff Cambra, CEO of SpinaFX [Photo courtesy of SpinaFX]Jeff Cambra is the new CEO of SpinaFX Medical, the back pain therapy startup said on October 1.

Cambra was previously a vice president at Zimmer Biomet (NYSE:ZBH), “leading product management for their $5 billion global reconstruction business,” SpinaFX said in a news release. He served in that role from November 2020 to June 2021, according to his LinkedIn page.

He ended a nearly 11-year career at Medtronic (NYSE:MDT) in 2020, ultimately serving as vice president and general manager of interventional therapies. SpinaFX said he “led a successful turnaround of their $400 million vertebral augmentation and oncology business through new technology innovation, strategic partnerships, acquisitions and expanding margins.”

Get the full story at our sister site Medical Design & Outsourcing. 

Read more
  • 0

AdvaMed honors former BD CEO Ludwig with its Lifetime Achievement Award

Former BD CEO Edward Ludwig

AdvaMed this week honored former BD CEO Edward Ludwig with its 2021 AdvaMed Lifetime Achievement Award.

Ludwig received the award on September 27 during an in-person and live-streamed event as part of The MedTech Conference.

Ludwig joined BD in 1979 and rose through the ranks to eventually become chair and CEO, retiring from the company in 2012.

AdvaMed in a news release praised the leadership that Ludwig demonstrated at BD:

He was instrumental in bringing the BD BACTEC 9000 system to market, a family of continuous blood monitoring and blood culturing instruments, revolutionizing the way blood culturing was performed, ultimately improving patient care and safety for health care workers.

With the goal of developing current and future leaders in the company, Ludwig established BD University, a management-driven leadership development program within the company. At BD, everyone who worked with him could tell you abo…

Read more
  • 0

Medical Alley appoints new CEO

The Medical Alley Association announced today that it appointed Roberta Dressen as its new president & CEO.

Dressen takes over the position previously held by Shaye Mandle since 2014 before he announced his departure for the Biotechnology Innovation Organization (BIO) in February. Steffen Hovard served as interim CEO in the time since then.

Get the full story at our sister site, MassDevice.

Read more
  • 0

Medical Alley appoints new CEO

The Medical Alley Association announced today that it appointed Roberta Dressen as its new president & CEO.

Dressen takes over the position previously held by Shaye Mandle since 2014 before he announced his departure for the Biotechnology Innovation Organization (BIO) in February. Steffen Hovard served as interim CEO in the time since then.

Hovard will stay on board over the next several weeks to assist with the transition as Dressen will officially begin her new role next week, according to a news release.

“The Medical Alley Association has a strong reputation of leadership and innovation,” Dressen said in the release. “I look forward to joining MAA and partnering with other global healthcare leaders to find ways to better serve our members and stimulate collaboration around how we can bridge current gaps in the healthcare industry.”

Dressen holds nearly two decades of leadership experience with some of Medical Alley’s notable healthcar…

Read more
  • 0

Navidea Biopharmaceuticals makes board of directors changes

Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors.

Dublin, Ohio-based Navidea ‘s chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from those positions, effective immediately.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

One of FDA’s top lawyers leaves to join Greenberg Traurig

James C. Fraser, Greenberg Traurig

Greenberg Traurig recently announced that James C. Fraser, a former associate chief counsel for litigation at the FDA, has joined its Litigation and Health Care & FDA practices in Washington, D.C.

Fraser left FDA in August. He has more than 16 years of experience in life sciences litigation and most recently worked in conjunction with the U.S. Department of Justice representing the FDA in civil litigation throughout the United States.

Robert P. Charrow recently returned to Greenberg Traurig as senior chair of the firm’s Health Care & FDA Practice after a stint as HHS general counsel.

“Having worked with Jim for several years, I am certain that his significant ability to successfully litigate complex matters concerning pharmaceuticals, medical devices, and other FDA-regulated products is of tremendous value to our clients,” Charrow said in a news…

Read more
  • 0